南京科佰生物科技有限公司官方网站欢迎您的光临!
免费咨询热线: 4008-750-250
科研细胞
药靶细胞
标准品
NGS靶向捕获探针
TIGIT/NFAT-Luc/Jurkat
CBP74020 | |
I. Background | |
TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies. | |
II. Description | |
Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human TIGIT (V-set and immunoglobulin domain-containing protein 9, VSIG9, V-set and transmembrane domain-containing protein 3, and VSTM3, GenBank Accession No. NM_173799). |
|
III. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | TIGIT |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Synonym(s): | T-cell immunoreceptor with Ig and ITIM domains, V-set and immunoglobulin domain-containing protein 9, VSIG9, V-set and transmembrane domain-containing protein 3, VSTM3 |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+800ug/ml hygromycin+1ug/ml puromycin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
IV. Description of Host Cell Line | |
Organism: | Homo sapiens, human |
Tissue: | Peripheral blood |
Disease: | Acute T cell leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
Ⅴ. Representative Data | |
Figure 1.Recombinant Jurkat cell line expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of TIGIT. |
|
Figure 2. Dose response of anti-TIGIT neutralizing antibody in TIGIT/NFAT-Reporter Jurkat cell line (C26) with CD155/TCR activator-CHO, the EC50 was 1.24μg/ml. |
|

扫一扫,关注我们公众号
Copyright ©2021 www.cobioer.com All Rights Reserved. 南京科佰生物科技有限公司版权所有 苏ICP备13038923号